IONS - Latest News
Ionis Pharmaceuticals, Inc. (IONS), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $13.42B. Beta to the broader market is 0.37.
The article list below shows the most recent IONS headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent IONS Headlines
IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati
zacks.com - Jun 26, 2026
Ionis grants Recordati ex-U. S.
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridemia and Acute Pancreatitis Risk Reduction Transcript
seekingalpha.com - Jun 25, 2026
Ionis Pharmaceuticals, Inc.
FDA Expands IONS' Tryngolza Label to Treat Severe Hypertriglyceridemia
zacks.com - Jun 25, 2026
Ionis wins FDA approval to expand Tryngolza to severe hypertriglyceridemia, opening a broader market as the first approved treatment for the condition
Ionis Climbs As FDA Clears New Therapy To Lower Triglycerides, Pancreatitis Risk
benzinga.com - Jun 25, 2026
The U. S.
Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.
businesswire.com - Jun 25, 2026
CARLSBAD, Calif. --(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc.
How News Affects IONS Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track IONS's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked IONS news questions
- What is the latest IONS news headline?
- The most recent IONS headline (Jun 26, 2026) is "IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the IONS news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What IONS news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual IONS options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.